Possible scenario
Bull Case Holds
25% Chance
Investors treat the downgrade as a valuation call rather than a challenge to Moderna's science. Strong confidence in the FDA-approved mRNA flu vaccine and melanoma vaccine opportunity limits the damage.
Tickers
- MRNA+3.2%
Portfolio impact
S&P 500+0.0%
Each figure is the modeled move of the S&P 500 if the outcome occurs. For information only. Not investment advice.
Keeping an eye on this scenario?
Tilt can alert you when its probability or impact shifts, or send you a recommendation when it crosses a threshold.